trastuzumab SC (EG13074)
/ EirGenix
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 17, 2025
EGC102: Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.
(clinicaltrials.gov)
- P3 | N=0 | Withdrawn | Sponsor: EirGenix, Inc. | N=380 ➔ 0 | Not yet recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor
March 19, 2025
EGC102: Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared with EU-sourced Perjeta® (Pertuzumab) in Patients with HER2-positive Hormone Receptor Negative Early Breast Cancer.
(clinicaltrials.gov)
- P3 | N=380 | Not yet recruiting | Sponsor: EirGenix, Inc.
New P3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1